Amaryl: Advanced Glycemic Control for Type 2 Diabetes
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.23 | $36.98 (0%) | 🛒 Add to cart |
| 60 | $0.96 | $73.96 $57.62 (22%) | 🛒 Add to cart |
| 90 | $0.87 | $110.94 $78.26 (29%) | 🛒 Add to cart |
| 120 | $0.82 | $147.92 $98.90 (33%) | 🛒 Add to cart |
| 180 | $0.78 | $221.88 $141.04 (36%) | 🛒 Add to cart |
| 270 | $0.75 | $332.82 $202.10 (39%) | 🛒 Add to cart |
| 360 | $0.74
Best per pill | $443.76 $266.60 (40%) | 🛒 Add to cart |
| Product dosage: 3mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.40 | $42.14 (0%) | 🛒 Add to cart |
| 60 | $1.12 | $84.28 $67.08 (20%) | 🛒 Add to cart |
| 90 | $1.01 | $126.42 $91.16 (28%) | 🛒 Add to cart |
| 120 | $0.96 | $168.56 $115.24 (32%) | 🛒 Add to cart |
| 180 | $0.91 | $252.84 $164.26 (35%) | 🛒 Add to cart |
| 270 | $0.89 | $379.26 $239.08 (37%) | 🛒 Add to cart |
| 360 | $0.87
Best per pill | $505.68 $312.18 (38%) | 🛒 Add to cart |
Amaryl (glimepiride) is a second-generation sulfonylurea oral antidiabetic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It functions by stimulating insulin release from pancreatic beta cells and increasing peripheral tissue sensitivity to insulin. This medication is recognized for its once-daily dosing convenience and its role in comprehensive diabetes management strategies aimed at reducing the risk of long-term complications.
Features
- Active ingredient: Glimepiride
- Drug class: Sulfonylurea (insulin secretagogue)
- Available in tablet strengths: 1 mg, 2 mg, 4 mg
- Administration: Oral, once daily with breakfast or first main meal
- Onset of action: Approximately 2–3 hours
- Duration of action: Up to 24 hours
- Bioavailability: Nearly 100%
- Protein binding: >99%
- Metabolism: Hepatic (via CYP2C9)
- Excretion: Renal and fecal
Benefits
- Effectively lowers both fasting and postprandial blood glucose levels
- Convenient once-daily dosing supports medication adherence
- Demonstrates a lower incidence of hypoglycemia compared to some other sulfonylureas
- May be used as monotherapy or in combination with other antidiabetic agents
- Contributes to reduced HbA1c levels, helping patients achieve glycemic targets
- Supports long-term diabetes management and complication risk reduction
Common use
Amaryl is prescribed for the management of type 2 diabetes mellitus in adult patients when glycemic control cannot be achieved through diet and exercise alone. It is frequently utilized as first-line pharmacotherapy or as part of combination therapy regimens with other oral antidiabetic medications or insulin. Clinical use is guided by individual patient factors including renal function, age, and concomitant medications.
Dosage and direction
The recommended starting dose is 1–2 mg once daily, administered with breakfast or the first main meal of the day. Dosage adjustments should be made in increments of 1–2 mg at 1–2 week intervals based on blood glucose response. The maximum recommended dose is 8 mg once daily. For patients at increased risk of hypoglycemia (elderly, debilitated, or those with renal impairment), initiate therapy with 1 mg daily. The dosage should be individualized based on therapeutic response and tolerance.
Precautions
Regular monitoring of blood glucose and HbA1c is essential. Hepatic and renal function should be assessed periodically, as impairment may affect drug metabolism and elimination. Patients should be educated about recognizing and managing hypoglycemia. Use with caution in patients with G6PD deficiency due to risk of hemolytic anemia. Elderly patients are more susceptible to hypoglycemia; consider lower starting doses. Stress situations such as fever, trauma, infection, or surgery may require temporary insulin therapy.
Contraindications
Hypersensitivity to glimepiride or other sulfonylureas, sulfonamide derivatives, or any component of the formulation. Diabetic ketoacidosis, with or without coma. Type 1 diabetes mellitus. Severe renal or hepatic impairment. Concomitant use with bosentan.
Possible side effect
Common adverse reactions include hypoglycemia (2–4%), dizziness (1–2%), asthenia (1–2%), headache (1–2%), and nausea (1%). Less frequent effects include allergic skin reactions, hematological changes (leukopenia, thrombocytopenia), hyponatremia, and elevated liver enzymes. Severe hypoglycemia, though uncommon, represents the most serious potential adverse effect, particularly in elderly patients or those with renal impairment.
Drug interaction
Strong CYP2C9 inhibitors (fluconazole, amiodarone) may increase glimepiride concentrations. Beta-blockers, clonidine, and MAO inhibitors may potentiate hypoglycemic effect. Thiazides, corticosteroids, phenothiazines, thyroid products, and estrogens may reduce hypoglycemic effect. Concomitant alcohol use may produce a disulfiram-like reaction. NSAIDs, sulfonamides, and warfarin may displace glimepiride from protein binding sites.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If remembered near the time of the next dose, skip the missed dose and resume the regular schedule. Do not double the dose to make up for a missed dose. Patients should monitor blood glucose levels more frequently if a dose is missed.
Overdose
Symptoms primarily consist of severe hypoglycemia including confusion, tremors, sweating, tachycardia, nausea, and potentially seizures or coma. Management involves immediate glucose administration (oral or intravenous depending on consciousness level). Continuous glucose monitoring and supportive care are essential. Hemodialysis is not effective due to high protein binding. Hospital observation for 24–48 hours may be necessary due to the prolonged hypoglycemic effect.
Storage
Store at controlled room temperature (20–25°C or 68–77°F). Protect from light and moisture. Keep in the original container with the lid tightly closed. Do not store in bathroom or other humid areas. Keep out of reach of children and pets. Do not use tablets that are discolored or show signs of deterioration.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions should be made in consultation with a qualified healthcare professional. Individual response to medication may vary. Patients should not discontinue or alter their dosage without medical supervision. The prescribing physician should be informed of all medications being taken, including over-the-counter products and supplements.
Reviews
Clinical studies demonstrate Amaryl’s efficacy in glycemic control with once-daily dosing convenience. In a 14-week study, 1–8 mg daily produced dose-dependent reductions in HbA1c (1.2–1.9%) and fasting plasma glucose (39–74 mg/dL). Combination therapy with metformin shows additive effects. Long-term data support sustained efficacy with appropriate dose titration. Patient satisfaction surveys indicate preference for once-daily regimen compared to multiple daily dosing regimens.